Ibex Technologies (TSXV:IBT) Debt-to-EBITDA : 1.35 (As of Jan. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Ibex Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ibex Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.26 Mil. Ibex Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$1.31 Mil. Ibex Technologies's annualized EBITDA for the quarter that ended in Jan. 2024 was C$1.16 Mil. Ibex Technologies's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was 1.35.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ibex Technologies's Debt-to-EBITDA or its related term are showing as below:

TSXV:IBT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -46.64 Med: 0.77 Max: 3.31
Current: 0.54

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ibex Technologies was 3.31. The lowest was -46.64. And the median was 0.77.

TSXV:IBT's Debt-to-EBITDA is ranked better than
64.6% of 274 companies
in the Biotechnology industry
Industry Median: 1.31 vs TSXV:IBT: 0.54

Ibex Technologies Debt-to-EBITDA Historical Data

The historical data trend for Ibex Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibex Technologies Debt-to-EBITDA Chart

Ibex Technologies Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.79

0.30

0.89

0.57

0.64

Ibex Technologies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-EBITDA	Get a 7-Day Free Trial															1.73	0.50	0.46	0.42	1.35

Competitive Comparison of Ibex Technologies's Debt-to-EBITDA

For the Biotechnology subindustry, Ibex Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ibex Technologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ibex Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ibex Technologies's Debt-to-EBITDA falls into.

Ibex Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ibex Technologies's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.213	+	1.426)	/	2.553
	=	0.64

Ibex Technologies's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.261	+	1.313)	/	1.164
	=	1.35

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.

Ibex Technologies (TSXV:IBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Ibex Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ibex Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibex Technologies (TSXV:IBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ibex Technologies Inc (TSXV:IBT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

IBXNF:USA IBT:Germany

Address

5485 Pare Street, Suite 100, Montreal, QC, CAN, H4P 1P7

Website

https://www.ibex.ca

Ibex Technologies Inc is a company engaged in the production and sale of diagnostic products. It manufactures and markets enzymes for biomedical use, through its subsidiaries. It also manufactures and markets a series of arthritis assays that have applications in osteoarthritis research. It sells two product lines namely, Enzymes for in-vitro diagnostics and research, and Tests for osteoarthritis research. The group provides services like Filing and lyophilization of disposable diagnostic components, and Custom fermentation and purification of enzymes for diagnostic companies. Geographically, the firm sells its products in Canada, Germany, the U.S., the U.K., and other countries of which the majority of the revenue is generated from the U.S.

Ibex Technologies (TSXV:IBT) Headlines

No Headlines